KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.

doi:10.1186/1471-2407-12-105

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.

BMC cancer - 22 Mar 2012

Cerne Jasmina-Ziva, Stegel Vida, Gersak Ksenija, Novakovic Srdjan

Abstract excerpt

BACKGROUND: A single nucleotide polymorphism located in the 3'-untranslated region of the KRAS oncogene (KRAS variant; rs61764370) disrupts a let-7 miRNA binding and was recently reported to act as a genetic marker for increased risk of developing human cancers. We aimed to investigate an association of the KRAS variant with sporadic and familial breast cancer and breast tumor characteristics. METHODS: Genotyping...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Genes, ras

Share to Hormone Replacement Therapy

Share to Logistic Models

Share to Postmenopause

Share to Receptor, ErbB-2

Share to Slovenia

Source

Open in PubMed Open full text

Identifiers

PMID: 22436609
DOI: 10.1186/1471-2407-12-105
PMCID: PMC3342891

Genes

KRAS
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.PMID 22436609Read ↗

Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.Semantic proximity Read ↗

A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.Semantic proximity Read ↗

KRAS 3'-UTR variants and stratification of breast-cancer risk.Semantic proximity Read ↗

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.Semantic proximity Read ↗

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.Semantic proximity Read ↗

Impact of KRAS variant rs61764370 on breast cancer morbidity.Semantic proximity Read ↗

The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.Semantic proximity Read ↗

Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population.Semantic proximity Read ↗

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.Semantic proximity Read ↗

Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.Semantic proximity Read ↗

Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer.Semantic proximity Read ↗

rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.